IMMUNE RESPONSE OF HCV INFECTION

HCV 感染的免疫反应

• 批准号: 6161489
• 负责人: J W SHIH
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6161489
• 关键词: antiviral antibody; chronic disease /disorder; clinical research; communicable disease diagnosis; epitope mapping; hepatitis C; hepatitis C virus; hepatitis vaccine; human subject; laboratory mouse; microorganism immunology; serology /serodiagnosis; synthetic vaccines; virus antigen; virus infection mechanism; virus protein

This is a continuous effort of a collaborative multi-phase project to investigate the immune response in both humans and experimental animals after their infection with human hepatitis C virus. In the initial phase, the commercial testing kits were used to detect antibodies to HCV proteins in the known non-A, non-B hepatitis patient sera. This provided information on the serological data of hepatitis C virus infection and its relationship to other clinical determinations. The second phase of the study will concentrate on the identification of immune dominant epitopes and neutralizing epitopes. The scope of this phase of study will be extensive and time-consuming. The third phase of the project will encompass using the knowledge of the immune response to develop preventive strategy and understanding of the pathogenicity of this viral infection. Special attention will be paid in identifying the possible relationship between the immune response and the high chronicity in HCV infected patients. One part of this study is to transfer techniques and procedures developed in the laboratory studies to our clinical studies. We have developed a proliferation assay to measure the immune response in mice to recombinant HCV core proteins. We then adopted the experience learned in working with mice to develop procedures to differentiate chronic infected patients from the recovered ones. During FY '95 and FY '96, we initiated a new project to examine the potential for a nucleic acid vaccine for HCV. The knowledge, the techniques and the material developed in this nucleic acid vaccine study will also complement our continued effort in understanding the immune response in HCV infection. The long-term goal of both projects will lead to developing models of immune therapy of chronic viral infection of the liver.

这是一个多阶段合作项目的持续努力， 研究人类和实验动物的免疫反应 感染了人类丙型肝炎病毒之后在初始阶段， 用市售试剂盒检测HCV蛋白抗体 在已知的非甲非乙型肝炎患者血清中。这提供 有关丙型肝炎病毒感染的血清学数据及其 与其他临床决定的关系。第二阶段 研究将集中在免疫优势表位的鉴定上 和中和表位。本阶段研究的范围将是 广泛和耗时。该项目的第三阶段将 包括利用免疫反应的知识来制定预防措施， 战略和了解这种病毒感染的致病性。 将特别注意确定可能的关系 HCV感染者的免疫应答与高慢性化之间的关系 患者这项研究的一部分是转移技术和程序， 在实验室研究中发展到我们的临床研究。我们有 开发了一种增殖试验来测量小鼠对 重组HCV核心蛋白。然后，我们采用了 用老鼠来开发区分慢性感染的程序， 从康复的病人中分离出来在1995和1996财政年度， 一个新的项目，以检查丙型肝炎病毒的核酸疫苗的潜力。 在这一领域发展起来的知识、技术和材料 酸性疫苗研究也将补充我们在以下方面的持续努力： 了解HCV感染的免疫反应。的长期目标 这两个项目将导致开发慢性免疫治疗模型， 肝脏的病毒感染。